IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
IRadimed CorporationNASDAQ: IRMD
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q1 FY2026 net change in cash was $5.22M, compared with -$1.9M a year earlier. Trailing-twelve-month net change in cash was $6.04M. Over 3 fiscal years it compounded at -35.7% a year.
Context
- Net change in cash amounted to 1.3% of revenue in FY2025, down 2.1 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near $5.22M or moves back toward the trailing-twelve-month quarterly average of $1.51M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (1.08M) USD
- Year-over-year change
- -143.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.08M) | -143.5% |
| FY2024 | 2024-12-31 | 2.47M | +130.1% |
| FY2023 | 2023-12-31 | (8.2M) | -103.0% |
| FY2022 | 2022-12-31 | (4.04M) | -133.9% |
| FY2021 | 2021-12-31 | 11.93M | — |
Net Change in Cash vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's LTM Mar 2026 net change in cash of $6.04M is the 8th largest of the 11 companies compared; the peer median is $14.17M.
- Its year-over-year change of +16.1% is the 6th highest of 11, against a peer median of +47.2%.
- Net change in cash amounts to 7.0% of revenue for IRMD, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $293.83M | +8968.7% | — | 110.1% | |
| LTM Mar 2026 | $248.35M | +892.7% | +71.1% | 66.3% | |
| LTM Mar 2026 | $125.75M | +2426.6% | -40.4% | 12.2% | |
| LTM Mar 2026 | $94.11M | -125.2% | — | 16.2% | |
| LTM Mar 2026 | $65.27M | -71.9% | +0.5% | 8.3% | |
| LTM Mar 2026 | $53.34M | -7.9% | — | 13.7% | |
| LTM Mar 2026 | $27.5M | +148.0% | -17.8% | 13.4% | |
| LTM Mar 2026 | $6.04M | +16.1% | -35.7% | 7.0% | |
| LTM Apr 2026 | $5.69M | -78.1% | -67.3% | 0.2% | |
| LTM Mar 2026 | $2.3M | -99.3% | -41.6% | 0.1% | |
CTEVClaritev Corporation | LTM Mar 2026 | $828K | +102.3% | — | 0.1% |
| Peer median (excluding IRMD) | $14.17M | +47.2% | -29.1% | 12.8% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Depreciation & Amortization | 1.41M | 670.67K | 765.18K | 817.66K | 1.17M |
| Deferred Income Tax | 523.61K | 57.1K | (1.17M) | (697.65K) | 0 |
| Stock-Based Compensation | 1.46M | 1.39M | 2.19M | 2.52M | 2.92M |
| Change in Working Capital | (1.58M) | (5.06M) | (5.91M) | 3.75M | (4.35M) |
| Accounts Receivables | (575.54K) | (8.24M) | 841.91K | 1.76M | (3.03M) |
| Inventory | (393.32K) | (1.31M) | (7.47M) | 3.13M | (1.38M) |
| Accounts Payables | 30.41K | 1.12M | (216.44K) | (861.62K) | (76K) |
| Other Working Capital | (637.72K) | 3.37M | 932.43K | (277.58K) | 135K |
| Other Non-Cash Items | 119.04K | 148.74K | 402.32K | (3.02K) | 2.73M |
| Operating Cash Flow | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M |
| Capital Expenditures | (741.76K) | (1.87M) | (8.01M) | (8.01M) | (7.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 1.39M | 500K | 0 | 0 | 0 |
| Other Investing Activities | (259.43K) | (1.05M) | (566.66K) | (811.75K) | (656K) |
| Investing Cash Flow | 648.24K | (1.37M) | (8.01M) | (8.82M) | (8.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 29.62K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | (12.56M) | (13.22M) | (13.68M) | (15.04M) |
| Other Financing Activities | 24.43K | (147.27K) | (433.6K) | (688.16K) | (2.56M) |
| Financing Cash Flow | 24.43K | (12.71M) | (13.66M) | (14.34M) | (17.6M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.93M | (4.04M) | (8.2M) | 2.47M | (1.08M) |
| Free Cash Flow | 10.52M | 8.17M | 5.46M | 17.62M | 17.18M |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.